Predicting cytotoxicity from heterogeneous data sources with Bayesian learning

Journal of Cheminformatics

Volumn 2, Issue 1, 2010, Pages

  Langdon, Sarah R ^a,b   Mulgrew, Joanna ^a   Paolini, Gaia V ^a,c   Van Hoorn, Willem P ^a,d  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^c Gaia Paolini Ltd   (United Kingdom)

^d Accelrys Limited UK   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 78650901912     PISSN: None     EISSN: 17582946     Source Type: Journal    
DOI: 10.1186/1758-2946-2-11     Document Type: Article

References (33)

1. The price of innovation: new estimates of drug development costs. A DiMasi Joseph W Hansen Ronald G Grabowski Henry, J Health Econ 2003 22 151 185 10.1016/S0167-6296(02)00126-1 12606142
2. Why drugs fail - a study on side effects in new chemical entities. D Schuster C Laggner T Langer, Curr Pharm Des 2005 11 3545 3559 10.2174/138161205774414510 16248807
3. The role of investigative molecular toxicology in early stage drug development. CJ Gross JA Kramer, Expert Opin Drug Saf 2003 2 147 159 10.1517/14740338.2.2.147 12904115
4. Replacement of in vivo acute oral toxicity studies by in vitro cytotoxicity methods: Opportunities, limits and regulatory status. U Ukelis PJ Kramer K Olejniczak SO Mueller, Regul Toxicol Pharmacol 2008 51 108 118 10.1016/j.yrtph.2008.02.002 18362045
5. First dose of potential new medicines to humans: how animals help. P Greaves A Williams M Eve, Nat Rev Drug Discovery 2004 3 226 236 10.1038/nrd1329
6. The role of early in vivo toxicity testing in drug discovery toxicology. MR Fielden KL Kolaja, Expert Opin Drug Saf 2008 7 107 110 10.1517/14740338.7.2. 107 18324874
7. High Throughput Screening Identified a Substituted Imidazole as a Novel RANK Pathway-Selective Osteoclastogenesis Inhibitor. T Chen AC Knapp Y Wu J Huang JS Lynch JK Dickson Jr RM Lawrence JHM Feyen ML Agler, Assay Drug Dev Technol 2006 4 387 396 10.1089/adt.2006.4.387 16945012
8. An improved b-lactamase reporter assay: multiplexing with a cytotoxicity readout for enhanced accuracy of hit identification. TM Hallis AL Kopp J Gibson CS Lebakken M Hancock K Van Den Heuvel-Kramer T Turek-Etienne, J Biomol Screening 2007 12 635 644 10.1177/1087057107301499 (Pubitemid 47231233)
9. In Vitro Toxicology: Bringing The In Silico and In Vivo World Closer. JJ Xu, Computational Toxicology: Risk Assessment for Pharmaceutical and Environmental Chemicals New Jersey: John Wiley and Sons Inc, Ekins S, 1 2008 22 23
10. A neural network based classification scheme for cytotoxicity predictions:Validation on 30,000 compounds. L Molnar GM Keseru A Papp Z Lorincz G Ambrus F Darvas, Bioorg Med Chem Lett 2006 16 1037 1039 10.1016/j.bmcl.2005. 10.079 16288868
11. Utilizing high throughput screening data for predictive toxicology models: protocols and application to MLSCN assays. R Guha SC Schurer, J Comput-Aided Mol Des 2008 22 367 384 10.1007/s10822-008-9192-9 18283419
12. Data mining the NCI60 to predict generalized cytotoxicity. AC Lee K Shedden GR Rosania GM Crippen, J Chem Inf Model 2008 48 1379 1388 10.1021/ci800097k 18588283
13. Evaluation of machine-learning methods for ligand-based virtual screening. B Chen RF Harrison G Papadatos P Willett DJ Wood XQ Lewell P Greenidge N Stiefl, J Comput-Aided Mol Des 2007 21 53 62 10.1007/s10822-006- 9096-5 17205373
14. Bayesian screening for active compounds in high-dimensional chemical spaces combining property descriptors and molecular fingerprints. M Vogt J Bajorath, Chem Biol Drug Des 2008 71 8 14 18069988
15. Global mapping of pharmacological space. GV Paolini RHB Shapland WP van Hoorn JS Mason AL Hopkins, Nat Biotechnol 2006 24 805 815 10.1038/nbt1228 16841068
16. Classification of Kinase Inhibitors Using a Bayesian Model. X Xia EG Maliski P Gallant D Rogers, J Med Chem 2004 47 4463 4470 10.1021/jm0303195 15317458
17. Greater Than the Sum of Its Parts: Combining Models for Useful ADMET Prediction. SE O'Brien MJ De Groot, J Med Chem 2005 48 1287 1291 15715500
18. An accurate and interpretable Bayesian classification model for prediction of hERG liability. H Sun, ChemMedChem 2006 1 315 322 10.1002/cmdc.200500047 16892366
19. Enrichment of High-Throughput Screening Data with Increasing Levels of Noise Using Support Vector Machines, Recursive Partitioning, and Laplacian-Modified Naive Bayesian Classifiers. M Glick JL Jenkins JH Nettles H Hitchings JW Davies, J Chem Inf Model 2006 46 193 200 10.1021/ci050374h 16426055
20. Enrichment of extremely noisy high-throughput screening data using a naive Bayes classifier. M Glick AE Klon P Acklin JW Davies, J Biomol Screening 2004 9 32 36 10.1177/1087057103260590
21. Finding More Needles in the Haystack: A Simple and Efficient Method for Improving High-Throughput Docking Results. AE Klon M Glick M Thoma P Acklin JW Davies, J Med Chem 2004 47 2743 2749 10.1021/jm030363k 15139752
22. Searching Chemical Space with the Bayesian Idea Generator. WP van Hoorn AS Bell, J Chem Inf Model 2009 49 2211 2220 10.1021/ci900072g 19788263
23. Molecular Similarity Searching Using Atom Environments, Information-Based Feature Selection, and a Naive Bayesian Classifier. A Bender HY Mussa RC Glen S Reiling, J Chem Inf Comput Sci 2004 44 170 178 14741025
24. PubChem: a public information system for analyzing bioactivities of small molecules. Y Wang J Xiao TO Suzek J Zhang J Wang SH Bryant, Nucleic Acids Res 2009 37 623 W633 10.1093/nar/gkp456 19498078
25. Compound Cytotoxicity Profiling Using Quantitative High-Throughput Screening. M Xia R Huang KL Witt N Southall J Fostel MH Cho A Jadhav CS Smith J Inglese CJ Portier,, et al. Environ Health Perspect 2007 116 284 291 10.1289/ehp.10727
26. An introduction to ROC analysis. T Fawcett, Pattern Recogn Lett 2006 27 861 874 10.1016/j.patrec.2005.10.010
27. Does this stuff really work? D Rogers, 2007 Pipeline Pilot European User Group Meeting Pistoia, Italy 2007
28. Physiochemical drug properties associated with in vivo toxicological outcomes. JD Hughes J Blagg DA Price S Bailey GA DeCrescenzo RV Devraj E Ellsworth YM Fobian ME Gibbs RW Gilles,, et al. Bioorg Med Chem Lett 2008 18 4872 4875 10.1016/j.bmcl.2008.07.071 18691886
29. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. CA Lipinski F Lombardo BW Dominy PJ Feeney, Adv Drug Delivery Rev 1997 23 3 25 10.1016/S0169-409X(96) 00423-1 (Pubitemid 27046991)
30. How Desirable Are Your IC50s? A Way to Enhance Screening-Based Decision Making. GV Paolini RA Lyons P Laflin, J Biomol Screen 2010 15 1183 93 10.1177/1087057110384402 20980692
31. Pipeline Pilot version 7.5.2. Accelrys, Inc.: San Diego, CA 2008
32. Cheminformatics analysis and learning in a data pipelining environment. M Hassan RD Brown S Varma-O'Brien D Rogers, Mol Diversity 2006 10 283 299 10.1007/s11030-006-9041-5 (Pubitemid 44546683)
33. Cytoscape: A software environment for integrated models of biomolecular interaction networks. P Shannon A Markiel O Ozier NS Baliga JT Wang D Ramage N Amin B Schwikowski T Ideker, Genome Res 2003 13 2498 2504 10.1101/gr.1239303 14597658